Skip to main content

Table 1 Days of work missed

From: Interference with work in fibromyalgia - effect of treatment with pregabalin and relation to pain response

  Mean number (SD) of days of work missed per week at trial beginning Mean number (SD) of days of work missed per week at trial end Statistical significance
Pregabalin dose (n)    
Placebo (557) 2.2 (2.3) 1.9 (2.1) **
300 mg (547) 2.4 (2.3) 1.9 (2.1) ****
450 mg (553) 2.1 (2.2) 1.7 (2.0) ***
600 mg (561) 2.1 (2.2) 1.6 (2.0) ***
Pain improvement (n)    
Pain worse (221) 1.9 (2.1) 1.9 (2.1) NS
0-15% (281) 2.5 (2.4) 2.2 (2.2) NS
15-30% (233) 2.4 (2.2) 1.7 (2.0) ***
30-50% (319) 2.1 (2.2) 1.1 (1.7) ****
≥50% (435) 2.0 (2.2) 0.97 (1.6) ****
VAS pain score at trial end (n)    
>50 mm (1042) 2.4 (2.3) 2.1 (2.1) *
>30-50 mm (340) 1.9 (2.0) 1.1 (1.7) ****
0-30 mm (436) 1.9 (2.2) 0.73 (1.4) ****
  1. Days of work missed per week at the beginning and end of trials as assessed by the question "How many days in the past week did you miss work, including housework, because of fibromyalgia?" from the Fibromyalgia Impact Questionnaire (FIQ). Data are presented according to daily pregabalin dose, according to improvement in pain intensity scores over the course of the trials, and according to pain state at end of the trials; statistical significance for the comparison of trial end vs. beginning: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, NS - no significant difference. FIQ data were not available for trial 105, the only trial with a 150 mg pregabalin group. Therefore no data for participants treated with 150 mg pregabalin are presented here.